China Pioneer Pharma Holdings Limited
China Pioneer Pharma Holdings Limited 1345.HK Peers
See (1345.HK) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
---|---|---|---|---|---|---|
1345.HK | $2.19 | -0.90% | 2.54B | 15.64 | $0.14 | +3.26% |
6160.HK | $145.50 | +2.83% | 213.05B | -66.44 | -$2.19 | N/A |
0241.HK | $4.83 | -1.23% | 77.67B | 48.30 | $0.10 | N/A |
3613.HK | $8.72 | +0.23% | 7.30B | 14.53 | $0.60 | +3.79% |
3390.HK | $0.45 | -1.10% | 360.00M | 45.00 | $0.01 | +7.69% |
1110.HK | $0.56 | -1.75% | 330.18M | 7.00 | $0.08 | +6.43% |
2211.HK | $0.11 | -0.91% | 87.32M | 5.45 | $0.02 | N/A |
0348.HK | $0.09 | -2.11% | 71.65M | -1.86 | -$0.05 | N/A |
0574.HK | $0.03 | +6.67% | 47.20M | 1.60 | $0.02 | N/A |
Stock Comparison
1345.HK vs 6160.HK Comparison
1345.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 1345.HK stands at 2.54B. In comparison, 6160.HK has a market cap of 213.05B. Regarding current trading prices, 1345.HK is priced at $2.19, while 6160.HK trades at $145.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
1345.HK currently has a P/E ratio of 15.64, whereas 6160.HK's P/E ratio is -66.44. In terms of profitability, 1345.HK's ROE is +0.14%, compared to 6160.HK's ROE of -0.12%. Regarding short-term risk, 1345.HK is less volatile compared to 6160.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1345.HK.